Zealand Pharma CEO before possible approval: We can take major leap

These weeks, Zealand Pharma is on the cusp of getting a crucial FDA approval. If the firm successfully attains this, it may transform the company, according to CEO Emmanuel Dulac.
Zealand Pharma President & CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH
Zealand Pharma President & CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Within the next two weeks, biotech firm Zealand Pharma might get hold of its first own approval. The US Food and Drug Administration (FDA) will present its evaluation on the firm's rescue pen for treating acute low blood sugar in diabetes patients before March 27.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading